Skip to content
Clinical Trials – home

Multiprofile Hospital For Active Treatment - Targovishte AD

Research site

Bulgaria West District, Syuren Blvd 1, 7700 Targovishte, Bulgaria

  • 2 trials recruiting
  • Schizophrenia · Cognitive disorder · Embolism venous
  • Adults and children

About Specializations

Multiprofile Hospital For Active Treatment - Targovishte AD in Targovishte, Bulgaria specialises in clinical trials of conditions such as Schizophrenia, Cognitive disorder, Embolism venous, Major depression, and other specialisations. This site conducts important research.

Main research areas of the site

Psychiatry and Psychology

At Multiprofile Hospital For Active Treatment - Targovishte AD, clinical research in Psychiatry and Psychology focuses on major depressive disorder and schizophrenia. The studies are aimed at evaluating new treatment options, assessing long-term safety, and understanding how therapies may improve symptoms and daily functioning.

  • Research on major depressive disorder is exploring ways to improve depression relief and support better treatment response.
  • Several trials examine schizophrenia in both adolescents and adults, with attention to symptom control and overall safety.
  • Some studies also look at cognitive and behavioral symptoms linked to schizophrenia, helping clarify treatment benefits beyond core psychotic symptoms.

The psychiatry team at this hospital contributes to studies that may help refine care for people living with complex mental health conditions.

Nervous System Diseases

Clinical trials in the area of Nervous System Diseases at the Psychiatry Department in Targovishte include research on schizophrenia and related cognitive disorder. These studies are designed to test new therapies and better understand their impact on cognition, behavior, and overall psychiatric stability.

  • Studies in schizophrenia are evaluating potential treatments for adults who need inpatient care as well as younger patients.
  • Research into cognitive disorder and cognitive impairment associated with schizophrenia aims to improve thinking and memory-related outcomes.
  • Ongoing work also includes assessment of treatment effectiveness and long-term tolerability in people with serious brain-related conditions.

This line of research reflects a broader effort to improve both symptom management and quality of life for patients affected by neurological and psychiatric disorders.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
West District, Syuren Blvd 17700 TargovishteBulgaria
Recruiting now
2 trials
Conditions studied
4

More sites in TargovishteBulgaria

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

8 clinical trials

Schizophrenia

Recruiting

A study to evaluate the effectiveness and safety of NBI-1117570 in adults with schizophrenia who require hospital treatment.

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:HTL0022537
  • Sponsor:Neurocrine Biosciences Inc.

Study of milsaperidone as an additional treatment for adults with Major Depressive Disorder who are already taking antidepressants

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:(1S)-1-[4-[3-[4-(6-FLUORO-1,2-BENZOXAZOL-3-YL)PIPERIDIN-1-YL]PROPOXY]-3-METHOXYPHENYL]ETHANOL
  • Sponsor:Vanda Pharmaceuticals Netherlands B.V.

Embolism venous

Not recruiting

Comparison of SRSD107 and enoxaparin to prevent blood clots in adults undergoing knee replacement surgery

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Enoxaparin Sodium
  • Sponsor:Sirius Therapeutics Inc.

Schizophrenia

Not recruiting

Study on the Effectiveness and Safety of Cariprazine for Adolescents (13-17 years) with Schizophrenia

Registered drug
Countries:BulgariaBulgaria
  • Participants:0–17 years
  • Substances:Cariprazine
  • Sponsor:Gedeon Richter Plc.

Cognitive disorder+1

Not recruiting

Study on RL-007 for Improving Cognitive Impairment in Schizophrenia Patients

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:(2R,3S)-2-Amino-3-Hydroxy-3-Pyridin-4-Yl-1-Pyrrolidin-1-Ylpropan-1-One (2R,3R)-2,3-Dihydroxybutanedioic Acid
  • Sponsor:Recognify Life Sciences Inc.
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:1-[6-Ethyl-8-Fluoro-4-Methyl-3-(3-Methyl-1,2,4-Oxadiazol-5-Yl)Quinolin-2-Yl]-N-(Oxan-4-Yl)Piperidin-4-Amine
  • Sponsor:Neumora Therapeutics Inc.
Countries:BulgariaBulgaria
  • Participants:18–64 years
  • Substances:1-[6-Ethyl-8-Fluoro-4-Methyl-3-(3-Methyl-1,2,4-Oxadiazol-5-Yl)Quinolin-2-Yl]-N-(Oxan-4-Yl)Piperidin-4-Amine
  • Sponsor:Neumora Therapeutics Inc.

Schizophrenia

Not recruiting

Study on the Safety and Tolerability of Cariprazine for Treating Schizophrenia in Adolescents Aged 13-17

Registered drugNo placebo
Countries:BulgariaBulgaria
  • Participants:0–17 years
  • Substances:Cariprazine
  • Sponsor:Gedeon Richter Plc.
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.